Kadidia Dienta joins Gresh and Fauria along with Dr. Reid Merryman. Kadidia discusses her battle with lymphoma cancer that begin in July 2020. Kadidia’s treatment included chemotherapy, CAR T therapy, and after two relapses with cancer, she is currently participating in a clinical trial that shows promise. 

Dr. Merryman is an attending physician in the Lymphoma Program at Dana-Farber Cancer Institute. His research focuses on the development of immune-based therapies for patients with lymphoma.

Kadidia Dienta joins Gresh and Fauria along with Dr. Reid Merryman. Kadidia discusses her battle with lymphoma cancer that begin in July 2020. Kadidia’s treatment included chemotherapy, CAR T therapy, and after two relapses with cancer, she is currently participating in a clinical trial that shows promise. 
Dr. Merryman is an attending physician in the Lymphoma Program at Dana-Farber Cancer Institute. His research focuses on the development of immune-based therapies for patients with lymphoma.

Hear stories of hope and inspiration for a cancer-free future from the annual WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance.

Hear stories of hope and inspiration for a cancer-free future from the annual WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance.

WEEI/NESN Jimmy Fund Radio-Telethon

Jimmy Fund Interview - Kadidia Dienta and Dr. Reid Merryman

Lisa Scherber talks about what the first day of the Jimmy Fund Telethon has been like so far and the stories that have touched her the most.

Lisa Scherber talks about what the first day of the Jimmy Fund Telethon has been like so far and the stories that have touched her the most.

Jimmy Fund Director Lisa Scherber recaps Day One so far

Arbella Insurance Vice President Gayle O'Connell brings a BIG donation check for the Jimmy Fund Radio Telethon.

Arbella Insurance Vice President Gayle O'Connell brings a BIG donation check for the Jimmy Fund Radio Telethon.

Gayle O'Connell and Arbella make a HUGE donation

Laurie H. Glimcher, MD, was named President and CEO of Dana-Farber Cancer
Institute in 2016. She is also Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.

A trailblazer in cancer research, Dr. Glimcher's research identified key
transcriptional regulators of protective immunity and the origin of pathophysiologic
immune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, skeletal biology, and translational medicine, and has contributed more than 350 scholarly articles and papers to medical literature.

Aside from her research efforts, Dr. Glimcher has been a staunch proponent of
improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed Dean of Weill Cornell Medicine in New York and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute, Dr. Glimcher is a magna cum laude graduate of Radcliffe College, and holds an MD degree cum laude from Harvard Medical School.

Laurie H. Glimcher, MD, was named President and CEO of Dana-Farber Cancer Institute in 2016. She is also Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.
A trailblazer in cancer research, Dr. Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, skeletal biology, and translational medicine, and has contributed more than 350 scholarly articles and papers to medical literature.
Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed Dean of Weill Cornell Medicine in New York and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute, Dr. Glimcher is a magna cum laude graduate of Radcliffe College, and holds an MD degree cum laude from Harvard Medical School.

Jimmy Fund Interview - Kadidia Dienta and Dr. Reid Merryman

In 1 playlist(s)

WEEI/NESN Jimmy Fund Radio-Telethon

Social links

Follow podcast

Recent clips